Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 20 |
| Active Pipeline (Recruiting Now) | 6 (3) |
| Completed vs Stopped Early | 5 / 3 (15.0%) |
| Median Closed Actual Enrollment | 70 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Addenbrooke's Hospital | Cambridge, Cambridgeshire | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04870333 | PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V | Phase II/III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Cambridge University Hospitals NHS Foundation Trust Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.